Abstract
Type 2 diabetes mellitus, defined by hyperglycaemia, is very common and carries long-term cardiovascular (CV) and renal risks. Management has evolved to consider CV and renal outcomes rather than hyperglycaemia alone. New sodium–glucose cotransporter 2 and glucagon-like peptide type 1 receptor agonists significantly improve CV and renal outcomes, providing excellent therapy options. However, metformin, an old, affordable and effective oral medication is still a first-line treatment.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Umpierrez GE, Klonoff DC. Diabetes technology update: use of insulin pumps and continuous glucose monitoring in the hospital. Diabetes Care. 2018;41(8):1579–89.
Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2019;41(2):255–323.
Jacob S, Krentz AJ, Deanfield J, et al. Evolution of type 2 diabetes management from a glucocentric approach to cardio-renal risk reduction: the new paradigm of care. Drugs. 2021;81(12):1373–9.
Davies MJ, D’Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74(10):1376–414.
White JR. A brief history of the development of diabetes medications. Diabetes Spectr. 2014;27(2):82–6.
Nathan DM, Buse JB, Davidson MB. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009;52(1):17–30.
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131):854–65.
Stratton IM, Cull CA, Adler AI, et al. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: a prospective observational study (UKPDS 75). Diabetologia. 2006;49(8):1761–9.
Inzucchi SE, Bergenstal RM, Buse JB. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2015;38(1):140–9.
ACCORD Study Group, Gerstein HC, Miller ME, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med. 2011;364(9):818–28.
Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
Packer M. Worsening heart failure during the use of DPP-4 inhibitors: pathophysiological mechanisms, clinical risks, and potential influence of concomitant antidiabetic medications. JACC Heart Fail. 2018;6(6):445–51.
Thomson SC, Vallon V. Renal effects of sodium-glucose co-transporter inhibitors. Am J Cardiol. 2019;124:S28-35.
Yamazaki T, Mimura I, Tanaka T, et al. Treatment of diabetic kidney disease: current and future. Diabetes Metab J. 2021;45(1):11–26.
Aziz KMA. Diabetic foot ulcer risk with diabetic kidney disease and renal failure among 10,680 patients. Sci Med J. 2021;3(4):345–54.
Perkovic V, Jardine MJ, Neal B. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
Turchin A, Hosomura N, Zhang H, et al. Predictors and consequences of declining insulin therapy by individuals with type 2 diabetes. Diabet Med. 2020;37(5):814–21.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and conflict of interest
C. Fenton, a contracted employee of Adis International Ltd/Springer Nature, and C. Kang, a salaried employee of Adis International Ltd/Springer Nature, declare no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability
Not applicable.
Rights and permissions
About this article
Cite this article
Fenton, C., Kang, C. Evolving Type 2 diabetes management focuses on clinical outcomes. Drugs Ther Perspect 38, 165–170 (2022). https://doi.org/10.1007/s40267-022-00903-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-022-00903-z